Foundation Medicine remains one of the chief contributors to ComboMATCH, the largest of its kind initiative to test effectiveness of biomarker-targeted cancer treatment combinations BOSTON--(BUSINESS ...
The initiative now includes Foundation Medicine's FoundationOne Liquid CDx assay to test new therapy combinations in select groups of adults and children with cancer.